Prihlásiť sa Zaregistrujte sa zadarmo

Dividendový výnos spoločnosti Abeona Therapeutics Inc

Aká je hodnota metriky Dividendový výnos spoločnosti Abeona Therapeutics Inc?

Hodnota metriky Dividendový výnos spoločnosti Abeona Therapeutics Inc je 0.00%

Aká je definícia metriky Dividendový výnos?



Dividendový výnos (Dividend yield) je pomer vyplatených dividendov na jednu akciu za posledný rok a trhovej hodnoty jednej akcie v percentách.

The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.

A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.

Dividendový výnos spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Abeona Therapeutics Inc

Čomu sa venuje spoločnosť Abeona Therapeutics Inc?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

Firmy s metrikou dividendový výnos podobnou spoločnosti Abeona Therapeutics Inc